Maxcyte (MXCT) Other Operating Expenses (2020 - 2026)

Maxcyte (MXCT) has 7 years of Other Operating Expenses data on file, last reported at $4.4 million in Q1 2026.

• On a quarterly basis, Other Operating Expenses fell 34.25% year-over-year to $4.4 million in Q1 2026; TTM through Mar 2026 was $24.2 million, a 21.13% decrease from a year earlier, with the FY2025 full-year figure at $28.6 million, down 7.15% from the prior year.
• Other Operating Expenses for Q1 2026 stood at $4.4 million, down from $7.9 million in the prior quarter.
• Over the last five years, Other Operating Expenses for MXCT reached as high as $10.1 million in Q4 2024 and fell as low as $4.2 million in Q1 2022.
• Historically, Other Operating Expenses has averaged $6.8 million across 5 years, with a median of $6.9 million in 2025.
• Across the five-year window, Other Operating Expenses soared 71.11% in 2023 and tumbled 34.25% in 2026, its largest moves.
• Year by year, Other Operating Expenses stood at $6.3 million in 2022, then jumped by 60.99% to $10.1 million in 2023, then advanced by 0.05% to $10.1 million in 2024, then slipped by 21.24% to $7.9 million in 2025, then tumbled by 43.96% to $4.4 million in 2026.
• Per Business Quant data, the three most recent Other Operating Expenses figures were $4.4 million in Q1 2026, $7.9 million in Q4 2025, and $5.0 million in Q3 2025.